Artiva Biotherapeutics, Inc. (ARTV)

Market Cap	269.85M
Revenue (ttm)	2.60M
Net Income (ttm)	-61.28M
Shares Out	24.29M
EPS (ttm)	-11.42
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	312,500
Open	9.94
Previous Close	10.00
Day's Range	9.68 - 11.40
52-Week Range	9.68 - 17.31
Beta	n/a
Analysts	Strong Buy
Price Target	21.25 (+91.27%)
Earnings Date	Nov 12, 2024

About ARTV

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematos...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 19, 2024
• Employees: 43
• Stock Exchange: NASDAQ
• Ticker Symbol: ARTV
• Website: https://www.artivabio.com

Financial Performance

In 2023, Artiva Biotherapeutics's revenue was $33.49 million, an increase of 579.21% compared to the previous year's $4.93 million. Losses were -$28.72 million, -51.15% less than in 2022.

Financial numbers in USD

Analyst Forecast

According to 5 analysts, the average rating for ARTV stock is "Strong Buy." The 12-month stock price forecast is $21.25, which is an increase of 91.27% from the latest price.

Price Target

$21.25

(91.27% upside)

Analyst Consensus: Strong Buy